Semenkovich, Nicholas P. http://orcid.org/0000-0001-5266-6734
Badiyan, Shahed N.
Samson, Pamela P.
Stowe, Hayley B.
Wang, Yun E.
Star, Rachel
Devarakonda, Siddhartha
Govindan, Ramaswamy
Waqar, Saiama N.
Robinson, Clifford G. http://orcid.org/0000-0002-1399-9904
Vlacich, Gregory
Pellini, Bruna http://orcid.org/0000-0003-0898-0202
Chaudhuri, Aadel A. http://orcid.org/0000-0003-3115-3061
Funding for this research was provided by:
V Foundation for Cancer Research
WUSTL | Washington University School of Medicine in St. Louis (Siteman Cancer Fund)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U2C CA252981)
Article History
Received: 13 March 2023
Accepted: 30 August 2023
First Online: 2 October 2023
Competing interests
: N.P.S. and A.A.C. have patent filings related to lung cancer detection. N.P.S. has served as a consultant/advisor to Acuta Capital Management. S.N.B. has done consulting work with Merck. P.P.S. reports no disclosures. H.B.S. reports no disclosures. Y.E.W. was an employee of Tempus Labs, Inc. at the time of the study. R.S. is an employee of Tempus Labs, Inc. S.D. reports membership on advisory boards for AstraZeneca, Merus, Jazz, and Genentech. R.G. reports consulting roles at Merck and Inivata. S.N.W. reports funding from SWOG-Clinical Trials Partnership which provides effort for S.N.W to support and oversee the Lung-MAP master protocol and sub-study activities. S.N.W has done advisory board work for AstraZeneca and reports research support to her institution for clinical trials for which she is site PI: AbbVie Inc, Ariad Pharmaceuticals, Genentech, Immunomedics, Inc., Millennium Pharmaceuticals Inc, Roche, Astellas Pharma Inc, Daiichi Sankyo, Cullinan Pearl, Verastem Inc, GlaxoSmithKline/GSK, Janssen Research & Development LLC, Elevation Oncology, Genentech, Loxo Oncology, Takeda Pharmaceuticals. C.G.R. reports leadership roles and ownership interests in Radialogica and has patent filings related to treatment of cardiac arrhythmias. C.G.R. has done consulting/advisory work with Varian Medical Systems, AstraZeneca, EMD Serono, and Quantaras, and he receives research funding from Varian Medical Systems and Merck. G.V. reports no disclosures. B.P. receives research funding from the Bristol Myers Squibb Foundation/the Robert A. Winn Diversity in Clinical Trials Awards Program (to the institution), has received research support from Bristol Myers Squibb (to the institution), speaker honoraria from BioAscend, Merck, MJH Life Science, Play to Know AG, Grupo Pardini, GBOT, Foundation Medicine, and has done consulting/advisory board work with Guidepoint, Guardant Health, Illumina, Regeneron and AstraZeneca. A.A.C. has patent filings related to cancer biomarkers, and has licensed technology to Droplet Biosciences, Tempus Labs, LiquidCell Dx, and Biocognitive Labs. A.A.C. has served as a consultant/advisor to Roche, Tempus, Geneoscopy, NuProbe, Illumina, Invitae, Myriad Genetics, Daiichi Sankyo, AstraZeneca, AlphaSights, DeciBio, and Guidepoint. A.A.C. has received honoraria from Roche, Foundation Medicine, Agilent, Binaytara Foundation, and Dava Oncology. A.A.C. has stock options in Geneoscopy, research support from Roche, Illumina and Tempus Labs, and leadership roles and ownership interests in Droplet Biosciences and LiquidCell Dx.